Vanguard Group Inc. Reduces Position in Dianthus Therapeutics, Inc. $DNTH

Key Points

• Vanguard Group Inc. has reduced its stake in Dianthus Therapeutics by 13.0%, owning approximately $20.1 million worth of shares after selling 165,763 shares.
• Dianthus Therapeutics faces challenges with a reported EPS of ($0.88) last quarter, falling short of analysts' expectations, with a forecast of -2.61 EPS for the current fiscal year.
• Analysts have given the stock an average rating of "Buy" with a consensus price target of $54.00, indicating positive growth expectations despite current performance issues.

Vanguard Group Inc. cut its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 13.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,108,875 shares of the company's stock after selling 165,763 shares during the quarter. Vanguard Group Inc. owned 3.45% of Dianthus Therapeutics worth $20,115,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its position in Dianthus Therapeutics by 14.0% during the 4th quarter. JPMorgan Chase & Co. now owns 12,129 shares of the company's stock worth $264,000 after buying an additional 1,490 shares during the last quarter. Invesco Ltd. increased its stake in shares of Dianthus Therapeutics by 7.4% during the fourth quarter. Invesco Ltd. now owns 11,521 shares of the company's stock worth $251,000 after acquiring an additional 790 shares during the period. Barclays PLC raised its holdings in Dianthus Therapeutics by 2.6% during the fourth quarter. Barclays PLC now owns 42,766 shares of the company's stock worth $933,000 after purchasing an additional 1,082 shares in the last quarter. MetLife Investment Management LLC lifted its position in Dianthus Therapeutics by 3.1% in the fourth quarter. MetLife Investment Management LLC now owns 14,372 shares of the company's stock valued at $313,000 after purchasing an additional 433 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Dianthus Therapeutics by 21.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,468 shares of the company's stock valued at $207,000 after purchasing an additional 1,647 shares in the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DNTH. William Blair started coverage on Dianthus Therapeutics in a research note on Wednesday, July 2nd. They set an "outperform" rating for the company. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Wedbush raised their target price on Dianthus Therapeutics from $34.00 to $42.00 and gave the company an "outperform" rating in a report on Thursday, August 21st. Finally, Robert W. Baird lowered their price target on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 13th. Seven investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Dianthus Therapeutics has an average rating of "Buy" and a consensus price target of $54.00.

Dianthus Therapeutics Trading Up 1.6%

Shares of DNTH stock traded up $0.40 during mid-day trading on Thursday, reaching $24.66. The stock had a trading volume of 348,965 shares, compared to its average volume of 335,391. The company has a market cap of $793.81 million, a P/E ratio of -7.59 and a beta of 1.46. Dianthus Therapeutics, Inc. has a 12-month low of $13.36 and a 12-month high of $32.27. The business has a 50-day simple moving average of $21.10 and a 200 day simple moving average of $20.06.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The business had revenue of $0.19 million during the quarter, compared to analysts' expectations of $0.87 million. Research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.